 CARLSBAD, Calif., March 03, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e., COVID-19, announced that Thomas G. Wiggans, Chief Executive Officer, and Uri A. Lopatin, M.D., Chief Scientific Strategic Advisor, will present a company overview at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, 2022 at 11:10 a.m. PT 2:10 p.m. ET. The conference will take place virtually from March 7-9, 2022. 